The global oligonucleotide synthesis market was valued at $5197.50 million in 2020, and is projected to reach $26,099.90 million by 2030, registering a CAGR of 17.10% from 2021 to 2030.
Oligonucleotides are short fragments of nucleic acids that are synthesized using enzyme chemistry and genetic engineering. Oligonucleotide synthesis and recombinant DNA techniques provide an opportunity to construct genes for proteins that are not available in nature. Furthermore, oligonucleotides are used in laboratories for therapeutic, diagnostics, academic, and industrial procedures. They are also used for screening and initial research for target validation and drug production. Oligonucleotide synthesis occurs commercially to provide services for end users as well as for individual use such as DNA synthesizing. Oligonucleotides have a wide range of applications in medical science. Modern molecular testing and analytical methods (such as the polymerase chain reaction (PCR) and DNA sequencing), genomic library development, and artificial gene synthesis are all dependent on oligonucleotide in basic research and diagnostics.
Factors such as increase in government investments for synthetic biology and genome projects as well as R&D expenditure in pharmaceutical and biotechnology companies, increase in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications such as detection of autoimmune diseases, diagnosis of hepatitis, and SARS-COV2 virus boost the growth of the oligonucleotide synthesis market. In addition, increase in demand for high-end customized oligos and upgradation in purification of synthetic oligonucleotide and declination in cost of the oligonucleotide drugs further drive the growth of the oligonucleotide synthesis market.
However, complexities associated with therapeutic oligos and challenging delivery of oligonucleotide drugs to specific targets hinder the growth of the oligonucleotide synthesis market. On the contrast, growth opportunities in emerging economies and growing focus on personalized medicine create lucrative opportunities for the oligonucleotide synthesis market in the future.
The global oligonucleotide synthesis market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By application, it is classified into therapeutic applications, research applications, and diagnostic applications. On the basis of end user, it is classified into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic research institutes. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Oligonucleotides are short fragments of nucleic acids that are synthesized using enzyme chemistry and genetic engineering. Oligonucleotide synthesis and recombinant DNA techniques provide an opportunity to construct genes for proteins that are not available in nature. Furthermore, oligonucleotides are used in laboratories for therapeutic, diagnostics, academic, and industrial procedures. They are also used for screening and initial research for target validation and drug production. Oligonucleotide synthesis occurs commercially to provide services for end users as well as for individual use such as DNA synthesizing. Oligonucleotides have a wide range of applications in medical science. Modern molecular testing and analytical methods (such as the polymerase chain reaction (PCR) and DNA sequencing), genomic library development, and artificial gene synthesis are all dependent on oligonucleotide in basic research and diagnostics.
Factors such as increase in government investments for synthetic biology and genome projects as well as R&D expenditure in pharmaceutical and biotechnology companies, increase in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications such as detection of autoimmune diseases, diagnosis of hepatitis, and SARS-COV2 virus boost the growth of the oligonucleotide synthesis market. In addition, increase in demand for high-end customized oligos and upgradation in purification of synthetic oligonucleotide and declination in cost of the oligonucleotide drugs further drive the growth of the oligonucleotide synthesis market.
However, complexities associated with therapeutic oligos and challenging delivery of oligonucleotide drugs to specific targets hinder the growth of the oligonucleotide synthesis market. On the contrast, growth opportunities in emerging economies and growing focus on personalized medicine create lucrative opportunities for the oligonucleotide synthesis market in the future.
The global oligonucleotide synthesis market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By application, it is classified into therapeutic applications, research applications, and diagnostic applications. On the basis of end user, it is classified into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic research institutes. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global oligonucleotide synthesis market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of oligonucleotide synthesis used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product
- Oligonucleotide-based Drugs
- Synthesized Oligonucleotides
- Reagents
- Equipment
By Application
- Therapeutic Applications
- Research Applications
- Diagnostic Applications
By End-User
- Hospitals
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- CROs and CMOs
- Academic Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Alnylam Pharmaceuticals, Inc.
- Biogen Inc.
- Danaher Corporation
- Eurofins Scientific
- Ionis Pharmaceuticals, Inc.
- Kaneka Corporation
- LGC Limited
- Merck KGAA
- Sarepta Therapeutics, Inc.
- Thermo Fisher Scientific, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in government investments and R&D expenditure in pharmaceutical & biotechnology companies
3.5.1.2. Surge in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
3.5.1.3. Rise in demand for high end customized oligos and upgradation in purification
3.5.2. Restraints
3.5.2.1. Complexities associated with therapeutic oligos
3.5.2.2. Challenging delivery of oligonucleotide drugs to specific targets
3.5.3. Opportunities
3.5.3.1. Growth opportunities in emerging economies
3.5.3.2. Growing focus on personalized medicine
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the oligonucleotide synthesis market
CHAPTER 4: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Oligonucleotide-based drugs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Synthesized oligonucleotides
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Reagents
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Equipment
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Therapeutic applications
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.2.3. Market size and forecast, by Product
5.3. Research applications
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.3.3. Market size and forecast, by Product
5.4. Diagnostic applications
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.4.3. Market size and forecast, by Product
CHAPTER 6: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Pharmaceutical & biotechnology companies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Diagnostic laboratories
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
6.5. CROs and CMOs
6.5.1. Market size and forecast
6.5.2. Market analysis, by country
6.6. Academic research institutes
6.6.1. Market size and forecast
6.6.2. Market analysis, by country
CHAPTER 7: OLIGONUCLEOTIDE SYNTHESIS, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U. S.
7.2.2.1.1. U. S. oligonucleotide synthesis market, by product
7.2.2.1.2. U. S. oligonucleotide synthesis market, by application
7.2.2.1.3. U. S. oligonucleotide synthesis market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada oligonucleotide synthesis, by product
7.2.2.2.2. Canada oligonucleotide synthesis market, by application
7.2.2.2.3. Canada oligonucleotide synthesis market, by end user
7.2.2.3. Mexico
7.2.2.3.1. Mexico oligonucleotide synthesis market, by product
7.2.2.3.2. Mexico oligonucleotide synthesis market, by application
7.2.2.3.3. Mexico oligonucleotide synthesis market, by end user
7.2.3. North America market size and forecast, by product
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany oligonucleotide synthesis market, by product
7.3.2.1.2. Germany oligonucleotide synthesis market, by application
7.3.2.1.3. Germany oligonucleotide synthesis market, by end user
7.3.2.2. France
7.3.2.2.1. France oligonucleotide synthesis market, by product
7.3.2.2.2. France oligonucleotide synthesis market, by application
7.3.2.2.3. France oligonucleotide synthesis market, by end user
7.3.2.3. UK
7.3.2.3.1. UK oligonucleotide synthesis market, by product
7.3.2.3.2. UK oligonucleotide synthesis market, by application
7.3.2.3.3. UK oligonucleotide synthesis market, by end user
7.3.2.4. Italy
7.3.2.4.1. Italy oligonucleotide synthesis market, by product
7.3.2.4.2. Italy oligonucleotide synthesis market, by application
7.3.2.4.3. Italy oligonucleotide synthesis market, by end user
7.3.2.5. Spain
7.3.2.5.1. Spain oligonucleotide synthesis market, by product
7.3.2.5.2. Spain oligonucleotide synthesis market, by application
7.3.2.5.3. Spain oligonucleotide synthesis market, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe oligonucleotide synthesis market, by product
7.3.2.6.2. Rest of Europe oligonucleotide synthesis market, by application
7.3.2.6.3. Rest of Europe oligonucleotide synthesis market, by end user
7.3.3. Europe market size and forecast, by product
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan Oligonucleotide synthesis market, by product
7.4.2.1.2. Japan oligonucleotide synthesis market, by application
7.4.2.1.3. Japan oligonucleotide synthesis market, by end user
7.4.2.2. China
7.4.2.2.1. China Oligonucleotide synthesis market, by product
7.4.2.2.2. China oligonucleotide synthesis market, by application
7.4.2.2.3. China Oligonucleotide synthesis market, by end user
7.4.2.3. Australia
7.4.2.3.1. Australia oligonucleotide synthesis market, by product
7.4.2.3.2. Australia oligonucleotide synthesis market, by application
7.4.2.3.3. Australia oligonucleotide synthesis market, by end user
7.4.2.4. India
7.4.2.4.1. India oligonucleotide synthesis market, by product
7.4.2.4.2. India oligonucleotide synthesis market, by application
7.4.2.4.3. India oligonucleotide synthesis market, by end user
7.4.2.5. South Korea
7.4.2.5.1. South Korea oligonucleotide synthesis market, by product
7.4.2.5.2. South Korea oligonucleotide synthesis market, by application
7.4.2.5.3. South Korea Oligonucleotide synthesis market, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific oligonucleotide synthesis market, by product
7.4.2.6.2. Rest of Asia-Pacific oligonucleotide synthesis market, by application
7.4.2.6.3. Rest of Asia-Pacific oligonucleotide synthesis market, by end user
7.4.3. Asia-Pacific market size and forecast, by product
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil oligonucleotide synthesis market, by product
7.5.2.1.2. Brazil oligonucleotide synthesis market, by application
7.5.2.1.3. Brazil oligonucleotide synthesis market, by end user
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia oligonucleotide synthesis market, by product
7.5.2.2.2. Saudi Arabia oligonucleotide synthesis market, by application
7.5.2.2.3. Saudi Arabia oligonucleotide synthesis market, by end user
7.5.2.3. South Africa
7.5.2.3.1. South Africa oligonucleotide synthesis market, by product
7.5.2.3.2. South Africa oligonucleotide synthesis market, by application
7.5.2.3.3. South Africa oligonucleotide synthesis market, by end user
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA oligonucleotide synthesis market, by product
7.5.2.4.2. Rest of LAMEA oligonucleotide synthesis market, by application
7.5.2.4.3. Rest of LAMEA oligonucleotide synthesis market, by end user
7.5.3. LAMEA market size and forecast, by product
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. ALNYLAM PHARMACEUTICALS, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BIOGEN LIMITED
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. CINVEN
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. DANAHER CORPORATION
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. EUROFINS SCIENTIFIC
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. IONIS PHARMACEUTICALS, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. KANEKA CORPORATION
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. MERCK KGAA
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. SAREPTA THERAPEUTICS, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. THERMO FISHER SCIENTIFIC, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developmentsLIST OF TABLES
TABLE 01. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030 ($BILLION)
TABLE 02. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020-2030 ($BILLION)
TABLE 03. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2030 ($BILLION)
TABLE 04. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020-2030 ($BILLION)
TABLE 05. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020-2030 ($BILLION)
TABLE 06. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030($BILLION)
TABLE 07. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 08. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 09. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 10. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 11. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 12. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTICS APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 13. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020-2030($MILLION)
TABLE 15. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030($MILLION)
TABLE 16. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030($MILLION)
TABLE 17. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY REGION, 2020-2030($MILLION)
TABLE 18. OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
TABLE 19. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020-2030($MILLION)
TABLE 20. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 21. U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 22. U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 23. U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 24. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 25. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 26. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 27. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 28. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 29. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 30. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 31. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET , BY APPLICATION, 2020-2030
TABLE 32. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 33. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 34. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 35. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 36. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 37. FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 38. FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 39. FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 40. UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 41. UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 42. UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 43. ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 44. ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 45. ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 46. SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 47. SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 48. SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 49. REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 50. REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 51. REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 52. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 53. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 54. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 55. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 56. JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 57. JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 58. JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 59. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 60. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 61. CHINA OLIGONUCLEOTIDE SYNTHESIS, BY END USER, 2020-2030
TABLE 62. AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 63. AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 64. AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 65. INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 66. INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 67. INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 68. SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 69. SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 70. SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 71. REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 72. REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 73. REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 74. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 75. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 76. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 77. LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 78. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 79. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 80. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 81. SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 82. SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 83. SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 84. SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 85. SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 86. SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 87. REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 88. REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 89. REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 90. LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 91. LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 92. LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 93. ALNYLAM: COMPANY SNAPSHOT
TABLE 94. ALNYLAM: OPERATING BUSINESS SEGMENTS
TABLE 95. ALNYLAM: PRODUCT PORTFOLIO
TABLE 96. ALNYLAM: KEY DEVELOPMENTS
TABLE 97. BIOGEN: COMPANY SNAPSHOT
TABLE 98. BIOGEN: OPERATING SEGMENTS
TABLE 99. BIOGEN: PRODUCT PORTFOLIO
TABLE 100. BIOGEN: KEY DEVELOPMENTS
TABLE 101. CINVEN: COMPANY SNAPSHOT
TABLE 102. CINVEN: OPERATING SEGMENTS
TABLE 103. CINVEN: PRODUCT PORTFOLIO
TABLE 104. DANAHER: COMPANY SNAPSHOT
TABLE 105. DANAHER: PRODUCT SEGMENTS
TABLE 106. DANAHER: PRODUCT PORTFOLIO
TABLE 107. DANAHER: KEY DEVELOPMENTS
TABLE 108. EUROFINS: COMPANY SNAPSHOT
TABLE 109. EUROFINS: PRODUCT PORTFOLIO
TABLE 110. EUROFINS: KEY DEVELOPMENTS
TABLE 111. IONIS: COMPANY SNAPSHOT
TABLE 112. IONIS: OPERATING BUSINESS SEGMENTS
TABLE 113. IONIS: PRODUCT PORTFOLIO
TABLE 114. IONIS: KEY DEVELOPMENTS
TABLE 115. KANEKA: COMPANY SNAPSHOT
TABLE 116. KANEKA: OPERATING SEGMENTS
TABLE 117. KANEKA: PRODUCT PORTFOLIO
TABLE 118. KANEKA: KEY DEVELOPMENTS
TABLE 119. MERCK: COMPANY SNAPSHOT
TABLE 120. MERCK: OPERATING SEGMENTS
TABLE 121. MERCK: PRODUCT PORTFOLIO
TABLE 122. MERCK: KEY DEVELOPMENTS
TABLE 123. SAREPTA: COMPANY SNAPSHOT
TABLE 124. SAREPTA: OPERATING BUSINESS SEGMENTS
TABLE 125. SAREPTA: PRODUCT PORTFOLIO
TABLE 126. SAREPTA: KEY DEVELOPMENTS
TABLE 127. THERMO FISHER: COMPANY SNAPSHOT
TABLE 128. THERMO FISHER: OPERATING SEGMENTS
TABLE 129. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 130. THERMO FISHER: KEY DEVELOPMENTSLIST OF FIGURES
FIGURE 01. OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25. ALNYLAM: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. BIOGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. DANAHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29. DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30. EUROFINS: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. EUROFINS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32. IONIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 33. IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. KANEKA: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. KANEKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. KANEKA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40. SAREPTA: NET SALES, 2018-2020 ($MILLION)
FIGURE 41. THERMO FISHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 42. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
Companies Mentioned
- Alnylam Pharmaceuticals Inc.
- Biogen Inc.
- Danaher Corporation
- Eurofins Scientific
- Ionis Pharmaceuticals Inc.
- Kaneka Corporation
- LGC Limited
- Merck KGAA
- Sarepta Therapeutics Inc.
- Thermo Fisher Scientific Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 243 |
| Published | July 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 5197.5 million |
| Forecasted Market Value ( USD | $ 26099.9 million |
| Compound Annual Growth Rate | 17.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
